Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis
Authors
Keywords
-
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 30, Issue 1, Pages 72
Publisher
Springer Nature
Online
2011-08-05
DOI
10.1186/1756-9966-30-72
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials
- (2011) Wen-Bin Zhou et al. BREAST CANCER RESEARCH AND TREATMENT
- Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer
- (2011) R. Coleman et al. BREAST CANCER RESEARCH AND TREATMENT
- Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809
- (2011) C.L. Shapiro et al. EUROPEAN JOURNAL OF CANCER
- The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: a meta-analysis
- (2011) Wen-Bin Zhou et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
- (2010) H. Eidtmann et al. ANNALS OF ONCOLOGY
- Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients
- (2010) Wen-Bin Zhou et al. BMC CANCER
- Three polymorphisms in interleukin-1β gene and risk for breast cancer: a meta-analysis
- (2010) Xiaoan Liu et al. BREAST CANCER RESEARCH AND TREATMENT
- Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01)
- (2010) Jeong Eun Kim et al. BREAST CANCER RESEARCH AND TREATMENT
- Randomized Trial of Adjuvant Zoledronic Acid in Postmenopausal Women With High-Risk Breast Cancer
- (2010) Ticiana Leal et al. Clinical Breast Cancer
- Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial
- (2010) Catherine Van Poznak et al. JOURNAL OF CLINICAL ONCOLOGY
- The Efficacy of Bisphosphonates in the Prevention of Vertebral, Hip, and Nonvertebral-Nonhip Fractures in Osteoporosis: A Network Meta-Analysis
- (2010) Jeroen P. Jansen et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC
- (2009) Stephanie L. Hines et al. BREAST CANCER RESEARCH AND TREATMENT
- Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis
- (2009) Davide Mauri et al. BREAST CANCER RESEARCH AND TREATMENT
- Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results
- (2009) Adam M. Brufsky et al. Clinical Breast Cancer
- Prevention of osteoporosis after breast cancer
- (2009) David M. Reid MATURITAS
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
- (2009) Michael Gnant et al. NEW ENGLAND JOURNAL OF MEDICINE
- Zoledronic Acid Prevents Bone Loss in Premenopausal Women Undergoing Adjuvant Chemotherapy for Early-Stage Breast Cancer
- (2008) Dawn L. Hershman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer
- (2008) Stephanie L. Hines et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started